<DOC>
	<DOCNO>NCT02265731</DOCNO>
	<brief_summary>This study evaluate safety pharmacokinetic profile venetoclax daily dose schedule Japanese participant hematological malignancy .</brief_summary>
	<brief_title>Study Evaluating Venetoclax Subjects With Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Participants must histologically document diagnosis NHL ( exhaust option consider standard care ) define World Health Organization classification scheme relapse follow refractory standard treatment RCHOP , RCVP , fludarabine base regimen . Participants lymphoproliferative disease consider consultation AbbVie medical monitor Relapsed refractory multiple myeloma participant must previously treat least one prior line therapy measurable disease Chronic lymphocytic leukemia/small lymphocytic lymphoma participant must relapse refractory standard treatment fludarabine base regimen alkylator base regimen Untreated AML subject Relapsed refractory AML subject must previously treat least one prior line therapy Eastern Cooperative Oncology Group ( ECOG ) performance score less equal 1 ; adequate bone marrow independent growth factor support per local laboratory reference range ; adequate coagulation , renal , hepatic function , per laboratory reference range Screening Participants history autologous allogenic stem cell transplantation must adequate blood count independent growth factor support recover transplantrelated toxicity ( ) least 100 day postautologous transplant ( multiple myeloma ) 6 month postautologous transplant ( NHL ) prior first dose study drug least 6 month postallogenic transplant ( multiple myeloma ) prior first dose study drug active graftversushost disease ( GVHD ) , i.e. , require treatment NHL participants undergone allogeneic stem cell transplant diagnose PostTransplant Lymphoproliferative Disease , Burkitt 's lymphoma , Burkittlike lymphoma , lymphoblastic lymphoma/leukemia Participant test positive HIV Participant cardiovascular disability status New York Heart Association Class great equal 2 Participant significant history renal , neurologic , psychiatric , pulmonary , endocrinologic , metabolic , immunologic , cardiovascular , hepatic disease opinion Investigator would adversely affect his/her participate study . Participant receive monoclonal antibody antineoplastic intent within 8 week prior first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>small lymphocytic lymphoma</keyword>
	<keyword>relapse chronic lymphocytic leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>refractory small lymphocytic lymphoma</keyword>
	<keyword>relapse multiple myeloma</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>relapse small lymphocytic lymphoma</keyword>
	<keyword>Lymphatic Diseases</keyword>
</DOC>